Abstract
Suicide gene therapy is a therapeutic strategy, in which cell suicide inducing transgenes are introduced into target cells. Inserting a toxin-encoding gene into a lentiviral vector leads to decreased efficiency of virus production due to lethal effect of toxin on packaging cells. In this study, we designed and constructed a transfer vector to express the toxin in transduced cells but not in packaging cells. Plasmid pLenti-F/GFP was constructed by cutting out R 5′LTR-R 3′LTR fragment with the AflII restriction endonuclease from a plasmid pLenti4-GW/H1/TO-laminshRNA, followed by ligating R 5′LTR-R 3′LTR fragment, constructed by three PCR stages. The promoter and GFP CDS were inserted in opposite strand. For lentiviral production, the HEK293T cell line was co-transfected with the PMD2G, psPAX2, and pLenti-F/GFP plasmids (envelope, packaging, and transfer plasmids).Viral vector titers were assayed. The HEK293T cell line was transduced with this virus. PCR was performed to confirm the presence of the promoter fragment between the R and U5 in 3′LTR. The lentivirus titers were approximately 2 × 105. The GFP expression was seen in 51 % of the HEK293T cells transduced with lentivirus. The PCR product size was 1440 bp confirming the promoter fragment position between the R and U5 in 3′LTR. The strategy enables us to use a broad spectrum of toxin genes in gene therapy and helps avoid the death of the packaging cells with lentiviral vectors carrying a toxin-encoding gene, thereby increasing the efficiency of viral production in packaging cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Escors, D., & Breckpot, K. (2010). Lentiviral vectors in gene therapy: their current status and future potential. Archivum Immunologiae et Therapiae Experimentalis, 58, 107–119.
Yazawa, K., Fisher, W. E., & Brunicardi, F. C. (2002). Current progress in suicide gene therapy for cancer. World Journal of Surgery, 26, 783–789.
Malecki, M. (2012). Frontiers in suicide gene therapy of cancer. Journal of Genetic Syndromes and Gene Therapy, 3, e114.
Salvatorelli, E., Menna, P., Cantalupo, E., Chello, M., Covino, E., Wolf, F. I., & Minotti, G. (2015). The concomitant management of cancer therapy and cardiac therapy. Biochimica et Biophysica Acta. doi:10.1016/j.bbamem.2015.01.003.
Springer, C. J., & Niculescu-Duvaz, I. (2000). Prodrug-activating systems in suicide gene therapy. The Journal of Clinical Investigation, 105, 1161–1167.
Duarte, S., Carle, G., Faneca, H., de Lima, M. C., & Pierrefite-Carle, V. (2012). Suicide gene therapy in cancer: Where do we stand now? Cancer Letters, 324, 160–170.
Zarogoulidis, P., Darwiche, K., Sakkas, A., Yarmus, L., Huang, H., Li, Q., et al. (2013). Suicide gene therapy for cancer—current strategies. Journal of Genetic Syndromes & Gene Therapy, 4, 16849.
Yang, W. S., Park, S. O., Yoon, A. R., Yoo, J. Y., Kim, M. K., Yun, C. O., & Kim, C. W. (2006). Suicide cancer gene therapy using pore-forming toxin, streptolysin O. Molecular Cancer Therapeutics, 5, 1610–1619.
Chen, H. (2012). Exploiting the intron-splicing mechanism of insect cells to produce viral vectors harboring toxic genes for suicide gene therapy. Molecular Therapy—Nucleic Acids, 1, e57.
Massuda, E. S., Dunphy, E. J., Redman, R. A., Schreiber, J. J., Nauta, L. E., Barr, F. G., et al. (1997). Regulated expression of the diphtheria toxin A chain by a tumor-specific chimeric transcription factor results in selective toxicity for alveolar rhabdomyosarcoma cells. Proceedings of the National Academy of Sciences USA, 94, 14701–14706.
Keyvani, K., Baur, I., & Paulus, W. (1999). Tetracycline-controlled expression but not toxicity of an attenuated diphtheria toxin mutant. Life Sciences, 64, 17124.
Wang, C. Y., Li, F., Yang, Y., Guo, H. Y., Wu, C. X., & Wang, S. (2006). Recombinant baculovirus containing the diphtheria toxin A gene for malignant glioma therapy. Cancer Research, 66, 5798–5806.
Kurayoshi, K., Ozono, E., Iwanaga, R., Bradford, A. P., Komori, H., & Ohtani, K. (2014). Cancer cell specific cytotoxic gene expression mediated by ARF tumor suppressor promoter constructs. Biochemical and Biophysical Research Communications, 450, 240–246.
Li, Y., McCadden, J., Ferrer, F., Kruszewski, M., Carducci, M., Simons, J., & Rodriguez, R. (2002). Prostate-specific expression of the diphtheria toxin A chain (DT-A): Studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. Cancer Research, 62, 2576–2582.
Kohlschutter, J., Michelfelder, S., & Trepel, M. (2010). Novel cytotoxic vectors based on adeno-associated virus. Toxins (Basel), 2, 2754–2768.
McTaggart, S., & Al-Rubeai, M. (2002). Retroviral vectors for human gene delivery. Biotechnology Advances, 20, 1–31.
Santhosh, C. V., Tamhane, M. C., Kamat, R. H., Patel, V. V., & Mukhopadhyaya, R. (2008). A lentiviral vector with novel multiple cloning sites: Stable transgene expression in vitro and in vivo. Biochemical and Biophysical Research Communications, 371, 546–550.
Freed, E. O. (2001). HIV-1 replication. Somatic Cell and Molecular Genetics, 26, 13–33.
Vecil, G. G., & Lang, F. F. (2003). Clinical trials of adenoviruses in brain tumors: A review of Ad-p53 and oncolytic adenoviruses. Journal of Neuro-oncology, 65, 237–246.
Sudarshan, S., Holman, D. H., Hyer, M. L., Voelkel-Johnson, C., Dong, J. Y., & Norris, J. S. (2005). In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. Cancer Gene Therapy, 12, 12–18.
Ozawa, T., Hu, J. L., Hu, L. J., Kong, E. L., Bollen, A. W., Lamborn, K. R., & Deen, D. F. (2005). Functionality of hypoxia-induced BAX expression in a human glioblastoma xenograft model. Cancer Gene Therapy, 12, 449–455.
Chen, H. (2012). Exploiting the intron-splicing mechanism of insect cells to produce viral vectors harboring toxic genes for suicide gene therapy. Molecular Therapy—Nucleic Acids, 1, e57.
Maxwell, I. H., Maxwell, F., & Glode, L. M. (1986). Regulated expression of a diphtheria toxin A-chain gene transfected into human cells: possible strategy for inducing cancer cell suicide. Cancer Research, 46, 4660–4664.
Goverdhana, S., Puntel, M., Xiong, W., Zirger, J. M., Barcia, C., Curtin, J. F., et al. (2005). Regulatable gene expression systems for gene therapy applications: progress and future challenges. Molecular Therapy, 12, 189–211.
Wang, Z., Tang, Z., Zheng, Y., Yu, D., Spear, M., Iyer, S. R., et al. (2010). Development of a nonintegrating Rev-dependent lentiviral vector carrying diphtheria toxin A chain and human TRAF6 to target HIV reservoirs. Gene Therapy, 17, 1063–1076.
Young, J., Tang, Z., Yu, Q., Yu, D., & Wu, Y. (2008). Selective killing of HIV-1-positive macrophages and T cells by the Rev-dependent lentivirus carrying anthrolysin O from Bacillus anthracis. Retrovirology, 5, 36.
Vigna, E., & Naldini, L. (2000). Lentiviral vectors: Excellent tools for experimental gene transfer and promising candidates for gene therapy. The Journal of Gene Medicine, 2, 308–316.
Pluta, K., & Kacprzak, M. M. (2009). Use of HIV as a gene transfer vector. Acta Biochimica Polonica, 56, 531–595.
Ghanbari, J. A., Salehi, M., Zadeh, A. K., Zadeh, S. M., Beigi, V. B., Ahmad, H. K., et al. (2014). A preliminary step of a novel strategy in suicide gene therapy with lentiviral vector. Advanced Biomedical Research, 3, 7.
Matrai, J., Chuah, M. K., & VandenDriessche, T. (2010). Recent advances in lentiviral vector development and applications. Molecular Therapy, 18, 477–490.
Acknowledgments
We are deeply grateful to all the colleagues of Department of Genetics and Molecular Biology. This work was supported by a grant from the Isfahan University of Medical Sciences.
Ethical standards
This article does not contain any studies with human participants or animals performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mohammadi, Z., Shariati, L., Khanahmad, H. et al. A Lentiviral Vector Expressing Desired Gene Only in Transduced Cells: An Approach for Suicide Gene Therapy. Mol Biotechnol 57, 793–800 (2015). https://doi.org/10.1007/s12033-015-9872-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12033-015-9872-3